SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is experiencing significant buzz following FDA approval for YARTEMLEA, its groundbreaking treatment for TA-TMA, which also includes pediatric use. The community is buzzing with excitement over its "first and only" approved status, anticipating a substantial re-rating and potential short squeeze, with many long-term holders eyeing significant upside and a possible buyout by NVO. Despite some discussions around potential profit-taking, a strong sense of long-term value and market opportunity prevails among investors.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA CRYPTO) is trending as a potentially undervalued infrastructure play, with its compliance-first architecture and impressive throughput of over 11 million transactions per second positioning it as critical global financial plumbing. The community is actively discussing its live integration with Bridge, a Stripe-owned fiat anchor, enabling seamless transfers between traditional banking and crypto for institutional flows. This makes KTA an early-stage opportunity for those seeking exposure to the future of financial systems.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is generating significant buzz and upward momentum, with the community actively celebrating notable price appreciation and continuous gains. Enthusiasts are rallying around an "unfolding prophecy" and "ETH season" narrative, firmly positioning $YEE as a compelling, generational meme coin to "study" and accumulate during market pullbacks.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to groundbreaking preliminary data from its FLAMINGO-01 trial, showing an impressive approximately 80% reduction in breast cancer recurrence rates, a development the community views as a significant de-risking event for the immunotherapy. This positive clinical update, coupled with an exceptionally high cost-to-borrow rate and a very low share float, is fueling intense investor speculation about an imminent short squeeze and potential strategic partnerships, as insiders continue to demonstrate strong conviction through share accumulation.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending amid strong community buzz, driven by discussions surrounding its notably low public float and the potential for a short squeeze following recent significant market activity. Many are highlighting that a substantial portion of shares are locked up for months, suggesting minimal dilution risk and drawing comparisons to other volatile low-float runners within the active Robotics/AI sector. Traders are actively debating market manipulation narratives alongside calls to hold for further upward momentum, especially as attention focuses on warrant exercisability in the coming weeks.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending after Apple CEO and board member Tim Cook's notable open-market purchase of its shares, which many in the community are interpreting as a strong vote of confidence. This insider buying has ignited conversations about a potential turnaround and short squeeze for the stock, which has recently faced headwinds from China sales and tariff concerns.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is a top trending stock following the landmark FDA approval of its oral Wegovy pill, a major development set to revolutionize the weight-loss market by offering a convenient, needle-free treatment option. The community is buzzing with optimism, anticipating significant long-term growth and market share expansion for NVO in the rapidly expanding GLP-1 sector, despite competitive dynamics.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending after Sanofi's definitive agreement to acquire the company for $15.50 per share in cash, representing a significant premium. This move bolsters Sanofi's adult immunization portfolio with Dynavax's Heplisav-B and a promising shingles vaccine candidate. The community is actively debating the acquisition price, with many long-term shareholders expressing disappointment and some speculating on the possibility of a higher bid.

Frequency Electronics, Inc. engages in the design, development, and manufacture of precision time and frequency generation technology. It operates through the FEI-NY and FEI-Zyfer business segments. The FEI-NY segment provides precision time, frequency generation, and synchronization products and subsystems that are found on-board satellites, in ground-based communication stations, and imbedded in moving platforms. The FEI-Zyfer segment designs, develops, and manufactures products for precision time and frequency generation and synchronization, primarily incorporating GPS technology. The company was founded by Martin B. Bloch on August 25, 1961 and is headquartered in Uniondale, NY.

Frequency Electronics, Inc.

Frequency Electronics is a top discussion point following strong Q2 sales and a record backlog, with the CEO hinting at significant upcoming contracts in quantum sensing and defense. The community actively highlights its critical role in initiatives like the Golden Dome and its low float, driving bullish price expectations as an underfollowed gem.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following recent FDA approval of AQVESME for anemia in adults with alpha- or beta-thalassemia, marking it as the only approved therapy for this rare blood disorder. The community is expressing significant optimism, anticipating upward movement as this decision broadens the company's therapeutic offerings. This development is driving conversations around the stock's potential within the rare disease sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update PR...

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option Palatin Technologies Announces Closing of Upsized...

Summit Therapeutics Inc. (SMMT) - 1100% jump in weekly message volumeThe biopharma company saw a sharp rise in retail chatter on Stocktwits last week, driven by growing analyst optimism around its cancer drug candidate, ivonescimab — a PD-1/VEGF bispecific antibody.&nbsp;Truist, which has a 'Buy' rating and a $35 price target on the stock, called the upcoming survival data from the HARMONi-2 trial of ivonescimab in non-small cell lung cancer one of the year's most anticipated biotech readouts.According to The Fly, Truist said its in-house biostatistics expert believes the study could exceed expectations and demonstrate statistical significance.&nbsp;In a note from late March, Citi said it had developed a "strong conviction" that HARMONi-2 has a 70% chance of delivering a favorable overall survival outcome by the expected year-end update.Meanwhile, Cantor Fitzgerald highlighted co-CEO and chairman Bob Duggan's early exercise of 4 million stock options at $1.58 — roughly four years before expiration — as "quite unusual" and "quite bullish."Retail sentiment for Summit on Stocktwits flipped to 'extremely bullish' from 'neutral' last week, and the stock's year-to-date gains have reached nearly 30%.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_7_10_22_AM_png_fc435b051c.webp" alt="Screenshot 2025-04-14 at 7.10.22 AM.png" width="1318" height="316"><figcaption>SMMT retail sentiment weekly shift, as of April 11. | source: Stocktwits</figcaption></figure>Palatin Technologies Inc. (PTN) - 600% jump in weekly message volumeCranbury, New Jersey-based Palatin said Thursday that the NYSE American plans to delist its common stock after the company failed to meet the exchange's minimum stockholders' equity requirement by the April 10 deadline.Palatin said it will appeal the decision by April 25 and expects its shares to continue trading on NYSE American during the appeal process.The biopharma company, which develops drugs targeting the melanocortin receptor system, currently runs clinical trials in obesity, dry eye disease, ulcerative colitis, diabetic nephropathy, and other ocular conditions.On Stocktwits, sentiment for Palatin plunged into 'extremely bearish' territory from 'extremely bullish' last week. The stock has lost over 85% this year.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_7_10_31_AM_png_723d397ddb.webp" alt="Screenshot 2025-04-14 at 7.10.31 AM.png" width="1318" height="316"><figcaption>PTN retail sentiment weekly shift, as of April 11. | source: Stocktwits</figcaption></figure>Recursion Pharmaceuticals Inc. (RXRX) - 500% jump in weekly message volumeShares of Recursion Pharmaceuticals received a big boost last week after the U.S. health regulator unveiled&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rxrx-stock-jumps-after-hours-as-fda-eyes-ai-drug-testing/chfrEfxRbB6">plans</a> to modernize drug testing methodologies.&nbsp;The FDA said it would begin replacing traditional animal testing for monoclonal antibody therapies and other drugs with more "human-relevant" methods, including artificial intelligence (AI) models.This aligns closely with Nvidia-backed Recursion's business model, which uses AI, machine learning, and automation to accelerate drug discovery.&nbsp;On Stocktwits, sentiment for Recursion climbed into the 'extremely bullish' zone from 'bullish' last week, with the stock's year-to-date losses reducing to about 16%.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_7_34_11_AM_png_ca5ce8aae3.webp" alt="Screenshot 2025-04-14 at 7.34.11 AM.png" width="1318" height="316"><figcaption>RXRX retail sentiment weekly shift, as of April 11. | source: Stocktwits</figcaption></figure>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX

Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025. 

Equity

This account has been verified as an official PTN representative.

Verified Account

Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.

Current Price	$16.30
Prev Close	$16.86
Open	$16.51
Dividend Yield	0.00%
50-Day Moving Average	$13.99
Beta	0.17
Avg. Volume	76,805.21
PE Ratio	-1.28

52-Week High	$72.50
52-Week Low	$1.75
Market Capitalization	$28.71M
EPS (Annual)	-$32.15
Price to Book	41.40
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PTN
Palatin Technologies Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest PTN News

PTNPalatin Technologies Inc.